9 episodes

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.

pharmaphorum Podcast pharmaphorum

    • Science
    • 3.0, 2 Ratings

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.

    Novartis, company culture and COVID-19: the pharmaphorum podcast

    Novartis, company culture and COVID-19: the pharmaphorum podcast

    Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future.

    We also looked at how Novartis’ own operations had to change in response to the coronavirus pandemic and the considerable challenges that presented him as its chief people and organisation officer.

    It’s a role that sees him responsible for the physical and mental wellbeing of 130,000 employees around the world, huge numbers of which had to rapidly transition to new ways of remote working.

    Steven also talked about how his company’s culture has already changed in response to COVID-19 and what he thinks the virus means for pharma’s future working practices.

    You can listen to episode 22 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast and Stitcher.

    • 20 min
    Amgen and science education: the pharmaphorum podcast

    Amgen and science education: the pharmaphorum podcast

    Harvard University launched LabXchange in January and the free science education platform has acquired new resonance during the COVID-19 lockdowns that saw millions of students around the world move to home schooling.

    LabXchange’s founding sponsor, with a contribution of $6.5 million, is Amgen and for this episode of the pharmaphorum podcast I spoke with Scott Heimlich, who’s vice president of the Amgen Foundation and director of philanthropy at Amgen Inc.

    He discussed his company’s work to support science education and how he hopes LabXchange will drive inclusion in the scientific process and spark collaboration.

    We also looked at how the platform might address the challenge of access to lab facilities that many aspiring scientists around the world face.

    For students and teachers looking to get quickly started with LabXchange’s digital science content Harvard have, as Scott explained, produced a remote learning cluster of content on teaching lab skills, building scientific literacy, experimental thinking and more.

    You can listen to episode 21 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast and Stitcher.

    • 22 min
    UK pharma leadership and COVID-19: the pharmaphorum podcast

    UK pharma leadership and COVID-19: the pharmaphorum podcast

    The COVID-19 pandemic has forced significant changes on the pharmaceutical industry as companies scramble to protect employees, ensure business continuity and maintain patient access to medicines.

    In this episode of the podcast I spoke with Dennise Broderick, who’s president and managing director for Galen to find out about how she has been leading during the coronavirus’ emergency phase.

    The podcast forms the first audio companion to our UK Leaders articles, which so far featured general managers from Takeda, Gilead and Daiichi Sankyo, with more in the pipeline.

    In the episode, Dennise discussed some of the leadership lessons she’s learned from COVID-19 about managing during a crisis, her career path to date and what a UK Leaders’ day usually looks like in normal circumstances.

    We also spoke more about her company, how it fits into the UK life sciences ecosystem and differs from publicly-owned pharma companies, and what growth plans – which include the acquisition of POA Pharma at the start of this year – look like.

    You can listen to episode 20 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast and Stitcher.

    • 21 min
    Eisai and Alexa skills in epilepsy: the pharmaphorum podcast

    Eisai and Alexa skills in epilepsy: the pharmaphorum podcast

    Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world one of the companies working in this area is Eisai.

    Chief strategy officer for the pharma firm’s neurology business group in the US, Alexander Scott joined the pharmaphorum podcast to talk about Eisai’s use of digital technology and its Alexa skill for those impacted by Lennox-Gastaut Syndrome (LGS).

    The Ella the Jellyfish Alexa skill was created with input from children living with the rare and severe form of childhood-onset epilepsy and aims to provide comfort to children, families and caregivers through song, storytelling, meditation and interactive games.

    Alexander talked about the emergence of voice technology like Amazon’s Alexa, its healthcare applications and how it can help with unmet patient needs in epilepsy.

    The launch of Eisai’s Alexa skill in epilepsy late last year followed Amazon’s announcement in April 2019 that its smart speaker could handle health information compliantly in the US and the summer news that the UK’s NHS has worked with Amazon’ Alexa team to offer health information by voice search.

    For its part, Eisai is aiming to go beyond providing healthcare information via Alexa to using the smart speaker to give support and solace to patients, families and carers.

    You can listen to episode 19 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast and Stitcher.

    • 14 min
    Digital health and interoperability: the pharmaphorum podcast

    Digital health and interoperability: the pharmaphorum podcast

    One of the biggest barriers to applying precision medicine to clinical trials and patient engagement is getting different digital health systems to talk to each other.

    Seqster is one company tackling such issues of interoperability, and its CEO and co-founder Ardy Arianpour joined the pharmaphorum podcast to discuss how it applies a person-centric approach to empowering patients.

    The San Diego-based tech start-up’s research portal gathers patient data, such as electronic health records, genetic information and fitness results from wearables, to improve the way health data can be shared.

    It’s an aim that’s high on the agenda of bodies such as the Centers for Medicare and and Medicaid Services (CMS) and the office of the National Coordinator for Health Information Technology (ONC) in the US, whose new interoperability rules have just been finalised.

    Seqster’s research portal currently connects users to over 3,000 healthcare providers and more than 100,000 hospitals and clinics in the US, giving patients a way to manage all their health data from one mobile app.

    The firm recently secured strategic investment from Takeda Pharmaceuticals, via its Takeda Digital Ventures arm. The pharma company has said it wants Seqster to be a ‘cornerstone’ of its digital health strategy, and Ardy also talked about what the deal involves.

    A biotech and digital health entrepreneur, he played an instrumental role in expanding genetic testing access with the launch of BRCA testing and was a key player in the 2013 landmark SCOTUS decision scrapping gene patents.

    Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics and served as SVP of Ambry Genetics, which was sold to Konica in 2017 for $1 billion.

    You can listen to episode 18 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast and Stitcher.

    • 20 min
    Roche, big data and patient outcomes: the pharmaphorum podcast

    Roche, big data and patient outcomes: the pharmaphorum podcast

    In the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data and how some of its partnerships have been performing.

    Megaw is a strategic partnerships lead at Roche Products in the UK, with responsibilities that include partnering with the NHS to leverage broad scale genomic profiling and meaningful data at scale.

    In episode 17 of the podcast he discussed what types of information is actually involved in big data, where AI/machine learning fits in and what Roche’s therapeutic area focuses are in this rapidly emerging area.

    We also touched on the privacy concerns patients, HCPs and health systems can have over the use of health data and the impact of GDPR and other regulations have on the use of big data.

    You can listen to episode 17 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series – in iTunes, Spotify, acast and Stitcher.

    • 31 min

Customer Reviews

3.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Science

Listeners Also Subscribed To